These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2365 related items for PubMed ID: 18555935

  • 1. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [Abstract] [Full Text] [Related]

  • 3. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [Abstract] [Full Text] [Related]

  • 5. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E, Lotronex Investigator Team.
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [Abstract] [Full Text] [Related]

  • 6. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
    Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM.
    Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
    [Abstract] [Full Text] [Related]

  • 7. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 8. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
    Chang L, Tong K, Ameen V.
    Am J Gastroenterol; 2010 Apr 15; 105(4):866-75. PubMed ID: 20197759
    [Abstract] [Full Text] [Related]

  • 9. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K, DeGarmo RG, Jhingran P, Bagby B, Decker C, Markowitz M, Carter E, Bobbitt W, Dahdul A, DeCastro E, Gringeri L, Johanson J, Levinson L, Mula G, Poleynard G, Stoltz RR, Truesdale R, Young D, Lotronex Investigator Team.
    Am J Gastroenterol; 2002 Dec 15; 97(12):3139-46. PubMed ID: 12492201
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials.
    Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M.
    Dis Colon Rectum; 2008 Dec 15; 51(12):1775-80. PubMed ID: 18465170
    [Abstract] [Full Text] [Related]

  • 11. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
    Komoto S, Miura S.
    Nihon Rinsho; 2006 Aug 15; 64(8):1487-90. PubMed ID: 16898618
    [Abstract] [Full Text] [Related]

  • 12. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr 15; 18(100):75-9. PubMed ID: 19585728
    [Abstract] [Full Text] [Related]

  • 13. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
    Nakai A, Diksic M, Kumakura Y, D'Souza D, Kersey K.
    Neurogastroenterol Motil; 2005 Apr 15; 17(2):212-21. PubMed ID: 15787942
    [Abstract] [Full Text] [Related]

  • 14. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
    Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM.
    Am J Gastroenterol; 2003 May 15; 98(5):1117-22. PubMed ID: 12809837
    [Abstract] [Full Text] [Related]

  • 15. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.
    Am J Gastroenterol; 2008 May 15; 103(5):1217-25. PubMed ID: 18477346
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
    Schoenfeld P.
    Gastroenterol Clin North Am; 2005 Jun 15; 34(2):319-35, viii. PubMed ID: 15862938
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW.
    Lancet; 2000 Mar 25; 355(9209):1035-40. PubMed ID: 10744088
    [Abstract] [Full Text] [Related]

  • 18. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW, Clark WK, Moore DJ, Whorwell PJ.
    Cochrane Database Syst Rev; 2007 Oct 17; (4):CD003960. PubMed ID: 17943807
    [Abstract] [Full Text] [Related]

  • 19. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ.
    Am J Manag Care; 2001 Jul 17; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [Abstract] [Full Text] [Related]

  • 20. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH.
    Expert Rev Gastroenterol Hepatol; 2010 Feb 17; 4(1):13-29. PubMed ID: 20136586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 119.